Riskpilot← Back to searchSign inGet full accessNormedi Finland OyAb
OYActiveY-tunnus 2599564-9Elielinaukio 5-BActivities of agents involved in the wholesale of other particular products · NACE 4618Est. 20142 employees
Revenue 2025
EUR 1,9M
+46% vs 2024
EBITDA margin
6.9%
-9% vs 2024
Equity ratio
55.2%
Financial strength
Net profit 2025
EUR 103K
-11% vs 2024
| Revenue | EUR 1,9M | +46% |
| EBITDA | EUR 132K | -9% |
| Net profit | EUR 103K | -11% |
| Total assets | EUR 1M | +28% |
| Equity | EUR 568K | +15% |
| Employees | 2 | — |
Legal name
Normedi Finland OyAb
Y-tunnus number
2599564-9
Legal form
Osakeyhtiö
NACE code
4618 · Activities of agents involved in the wholesale of other particular products
Founded
21. tammikuuta 2014
Share capital
EUR 2 500
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-09-30
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja, toimitusjohtaja ja hallituksen varajäsen kukin yksin
Company purpose
Bolaget skall sälja och marknadsföra medicintekniska produkter och bedriva därmed förenlig verksamhet.
Address
Elielinaukio 5-B
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 901 | 1 746 | 1 910 | 1 321 | 1 930 |
| Staff expenses | −128 | −210 | −180 | −172 | −204 |
| EBITDA | 138 | 230 | 266 | 145 | 132 |
| Depreciation & amort. | — | — | — | −0 | −0 |
| EBIT | 138 | 230 | 266 | 145 | 132 |
| Net financials | −1 | −5 | −4 | −1 | −3 |
| Profit before tax | 136 | 225 | 262 | 145 | 129 |
| Tax | 23 | 45 | 53 | 29 | 26 |
| Net profit | 113 | 180 | 209 | 116 | 103 |
| Item | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 340 | 485 | 481 | 806 | 1 030 |
| Equity | 92 | 191 | 212 | 495 | 568 |
| Long-term debt | 18 | — | — | 0 | 0 |
| Short-term debt | 231 | 294 | 270 | 311 | 462 |
| Total debt | 249 | 294 | 270 | 311 | 462 |
EBITDA margin
6.9%
This company
15.8%
Market median
-56% vs market
20202025
Equity ratio
55.2%
This company
38.2%
Market median
+45% vs market
20202025
Return on equity
18.1%
This company
18.4%
Market median
+2% vs market
20202025
Net profit margin
5.3%
This company
8.1%
Market median
-35% vs market
20202025
Asset turnover
1.87×
This company
1.12×
Market median
+67% vs market
20202025
Debt / equity
0.81×
This company
0.62×
Market median
+31% vs market
20202025
- Annual report 2025Filed via PRH / YTJ · Period 2024-10-01 – 2025-09-30
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-09-30
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
JS Chief Executive Officer | Chief Executive Officer | 2025 |
JP Deputy Member | Deputy Member | 2023 |
| Former (4) | ||
ØG Chief Executive Officer | Chief Executive Officer | 2014 – 2025 |
FL | Audit | 2022 – 2023 |
ME Deputy Member | Deputy Member | 2020 – 2023 |
AM Deputy Member | Deputy Member | 2014 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairperson | 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Normedi Finland OyAb also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øystein Granne Norling | Chief Executive Officer | 0 companies |
| Jesper Steffensen | Chief Executive Officer | 0 companies |
| Fredrik Leonard Vikström | Audit | 0 companies |
| Malin Elisabet Norling | Deputy Member | 0 companies |
| João Paulo Falcão Malagueira | Deputy Member | 0 companies |
| Anneli Maria Kangas | Deputy Member | 0 companies |
| Michelangelo Stefani | Chairperson | 0 companies |